Physician profile
Jihad S Moukdad
NPI 1235221094
$17,016.14
in general payments reported to CMS, 2019-2025
57 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,446 · 2020: $2,525 · 2021: $2,548 · 2022: $1,984 · 2023: $3,064 · 2024: $2,452 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,438 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,438.36 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,844.10 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $1,433.06 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $1,414.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,183.80 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Corcept Therapeutics | $1,161.90 | 2020-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,012.78 | 2019-2025 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $934.04 | 2024-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $873.56 | 2019-2025 | Xarelto, Spravato |
| Abbvie INC. | $844.90 | 2019-2024 | |
| Pfizer INC. | $695.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $513.04 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $372.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $326.39 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Horizon Therapeutics Plc | $324.09 | 2019-2023 | Tepezza |
| E.R. Squibb & Sons, L.L.C. | $322.22 | 2019-2025 | Eliquis, Camzyos |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jihad Moukdad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.